(AMLX) – FDA
-
Amylyx Pharma (AMLX) Announces Interim Data From Ongoing Phase 2 HELIOS Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
-
Amylyx Pharmaceuticals (AMLX) to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to AMLX Stock Lookup
